Two free tools, one trusted formula
Among the synthesized compounds, R3 exhibited the most prominent inhibition against COX-1/2 at various test concentrations, with significant potency with respect to standard drugs indomethacin and celecoxib
Pharmacodynamic effects of standard versus high caffeine doses in the developing brain of neonatal rats exposed to intermittent hypoxia
Disclosures: Maria Fernanda Raya Tonetti: Nothing to Disclose, Noemi Cabre: Nothing to Disclose, Marcos Fernandez Fondevila: Nothing to Disclose, Alvaro Eguileor: Nothing to Disclose, Bernd Schnabl: Mabwell Therapeutics: Consultant, Ambys Medicines: Consultant, Surrozen: Consultant, Nterica Bio: Stock privately held company, Axial Biotherapeutics: Grant/Research Support, Prodigy Biotech: Grant/Research Support, CymaBay Therapeutics: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, ChromoLogic: Grant/Research Support, Cristina Llorente: Nothing to Disclose 2633 ARBM-101 RESCUES FULMINANT WILSON DISEASE Eun-Jung Kim 1 Dasol Kim 1 Banu Akdogan 2 Mikkel Holm Vendelbo 3 Emilie Munk 4 Judith Sailer 5 Adriana Filipa Fontes 2 Jonas Engler 5 Dongsik Park 1 Hongjae Lee 1 Chunwon Jung 1 Byong-Keol Min 1 Eok Park 1 TaeWon Kim 1 Seoyoung Choi 6 So-yeon Kim 1 Alan DiSpirito 7 Thomas Sandahl 4 Weonbin Im 1 So-Young Eun 1 Hans Zischka 2 Valentina Medici 8 , 1 ARBORMED Co., Ltd., 2 Helmholtz Munich, 3 Aarhus University Hospital, 4 Aarhus University, 5 Technical University Munich, 6 ARBORMED Co., Ltd., 7 Iowa State University, 8 University of California Davis Background: Wilson disease (WD), a genetic disorder caused by disruptive mutations in the ATP7B gene, primarily manifests with copper accumulation in the liver and brain
Down-stream in CK-signalling we found DEGs within ARR (Arabidopsis response regulator
